In the BioHarmony Drug Report Database

"Preview" Icon

Blinatumomab

Blincyto (blinatumomab) is an antibody pharmaceutical. Blinatumomab was first approved as Blincyto on 2014-12-03. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. It is known to target B-lymphocyte antigen CD19 and T-cell surface glycoprotein CD3 epsilon chain.

 

Trade Name

 

Blincyto
 

Common Name

 

blinatumomab
 

ChEMBL ID

 

CHEMBL1742992
 

Indication

 

lymphoid leukemia, precursor cell lymphoblastic leukemia-lymphoma
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Blinatumomab structure rendering